Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies-Reference-Cited by-同舟云学术

Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies

Published:2021-07-26 Issue:10 Volume:20 Page:1237-1246
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Buonomo Antonio Riccardo¹,Viceconte Giulio¹,Zappulo Emanuela¹,Maraolo Alberto Enrico¹,Russo Cinzia Valeria²,Carotenuto Antonio²,Moccia Marcello²,Gentile Ivan¹

Affiliation:

1. Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples “Federico II”, Napoli, Italy

2. Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples “Federico II”, Napoli, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2021.1942454

Reference53 articles.

1. Monoclonal antibodies in MS: Mechanisms of action

2. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial